Drugs / SNS-301
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04034225 | Nov 2019 → Jun 2021 | head and neck squamous cell carcinoma | Sensei Biotherapeutics, Inc. | Terminated | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04217720 | Apr 2020 → Jan 2022 | chronic myelomonocytic leukemia, myelodysplastic syndrome | Sensei Biotherapeutics, Inc. | Withdrawn | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SNS-301 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04217720 ↗ |
| Route | Other | “intradermally delivered SNS-301” NCT04034225 ↗ |